These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36046810)

  • 1. An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis.
    Arabpour M; Paul S; Grauers Wiktorin H; Kaya M; Kiffin R; Lycke N; Hellstrand K; Martner A
    Oncoimmunology; 2022; 11(1):2115618. PubMed ID: 36046810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADP-ribosylating adjuvant reveals plasticity in cDC1 cells that drive mucosal Th17 cell development and protection against influenza virus infection.
    Arabpour M; Lebrero-Fernandez C; Schön K; Strömberg A; Börjesson V; Lahl K; Ballegeer M; Saelens X; Angeletti D; Agace W; Lycke N
    Mucosal Immunol; 2022 Apr; 15(4):745-761. PubMed ID: 35418673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103
    Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen.
    Mowat AM; Donachie AM; Jägewall S; Schön K; Löwenadler B; Dalsgaard K; Kaastrup P; Lycke N
    J Immunol; 2001 Sep; 167(6):3398-405. PubMed ID: 11544331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants.
    Simmons CP; Mastroeni P; Fowler R; Ghaem-maghami M; Lycke N; Pizza M; Rappuoli R; Dougan G
    J Immunol; 1999 Dec; 163(12):6502-10. PubMed ID: 10586042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC; Ekman L; Löwenadler B; Lycke NY
    J Immunol; 1997 Apr; 158(8):3936-46. PubMed ID: 9103464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM.
    Lycke N
    Cell Microbiol; 2004 Jan; 6(1):23-32. PubMed ID: 14678328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The nontoxic CTA1-DD adjuvant enhances protective immunity against Helicobacter pylori infection following mucosal immunization.
    Akhiani AA; Stensson A; Schön K; Lycke N
    Scand J Immunol; 2006 Feb; 63(2):97-105. PubMed ID: 16476008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal inoculate of influenza virus vaccine against lethal virus challenge.
    Fan X; Su Q; Qiu F; Yi Y; Shen L; Jia Z; Liang P; Zou Y; Bi S
    Vaccine; 2018 Jul; 36(29):4354-4361. PubMed ID: 29880240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M; Momot M; Goubier A; Gonindard C; Leung-Theung-Long S; Misseri Y; Bissery MC
    Vaccine; 2017 Mar; 35(11):1509-1516. PubMed ID: 28196735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Synthetic Long Peptides and XCL1 Fusion Proteins Results in Superior Tumor Control.
    Botelho NK; Tschumi BO; Hubbell JA; Swartz MA; Donda A; Romero P
    Front Immunol; 2019; 10():294. PubMed ID: 30863405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
    Agren L; Löwenadler B; Lycke N
    Immunol Cell Biol; 1998 Jun; 76(3):280-7. PubMed ID: 9682972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Safe and Non-Self-Immunogenic Mucosal Adjuvant by Recombinant Fusion of Cholera Toxin A1 Subunit with Protein Transduction Domain.
    Shim BS; Cheon IS; Lee E; Park SM; Choi Y; Jung DI; Yang E; Choi JA; Chun JY; Kim JO; Yun CH; Czerkinsky C; Song MK
    J Immunol Res; 2018; 2018():9830701. PubMed ID: 29707588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors.
    Maraskovsky E; Sjölander S; Drane DP; Schnurr M; Le TT; Mateo L; Luft T; Masterman KA; Tai TY; Chen Q; Green S; Sjölander A; Pearse MJ; Lemonnier FA; Chen W; Cebon J; Suhrbier A
    Clin Cancer Res; 2004 Apr; 10(8):2879-90. PubMed ID: 15102697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat shock protein-antigen fusions lose their enhanced immunostimulatory capacity after endotoxin depletion.
    Marincek BC; Kühnle MC; Srokowski C; Schild H; Hämmerling G; Momburg F
    Mol Immunol; 2008 Nov; 46(1):181-91. PubMed ID: 18804283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response profile elicited by the model antigen ovalbumin expressed in fusion with the bacterial OprI lipoprotein.
    Basto AP; Badenes M; Almeida SC; Martins C; Duarte A; Santos DM; Leitão A
    Mol Immunol; 2015 Mar; 64(1):36-45. PubMed ID: 25467796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
    Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
    J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses.
    Bagley K; Xu R; Ota-Setlik A; Egan M; Schwartz J; Fouts T
    Hum Vaccin Immunother; 2015; 11(9):2228-40. PubMed ID: 26042527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S; Yuan J; Xiang J
    J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The XCL1-Mediated DNA Vaccine Targeting Type 1 Conventional Dendritic Cells Combined with Gemcitabine and Anti-PD1 Antibody Induces Potent Antitumor Immunity in a Mouse Lung Cancer Model.
    Zhang K; Wuri Q; Cai Z; Qu X; Zhang S; Wu H; Wu J; Wang C; Yu X; Kong W; Zhang H
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.